- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Early Treatment with Sublingual Edaravone Dexborneol Enhances Recovery in acute ischemic stroke, finds study
Sublingual edaravone dexborneol can rapidly diffuse and absorbed through the oral mucosa after sublingual exposure. It is a multitarget brain cytoprotection which contains antioxidant and anti-inflammatory ingredients edaravone and dexborneol.An Original Investigation published in JAMA Neurology has concluded that sublingual edaravone dexborneol can enhance the chances of achieving...
Sublingual edaravone dexborneol can rapidly diffuse and absorbed through the oral mucosa after sublingual exposure. It is a multitarget brain cytoprotection which contains antioxidant and anti-inflammatory ingredients edaravone and dexborneol.
- Nine hundred fourteen patients of median age, 64 years, were randomly allocated to the edaravone dexborneol or placebo group.
- The edaravone dexborneol group had a significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization than the placebo group (64.4% vs 54.7% with a risk difference of 9.70% and an odds ratio of 1.50.
- The two groups had a similar adverse event rate (89.8% vs. 90.1%).
BDS, MDS in Periodontics and Implantology
Dr. Aditi Yadav is a BDS, MDS in Periodontics and Implantology. She has a clinical experience of 5 years as a laser dental surgeon. She also has a Diploma in clinical research and pharmacovigilance and is a Certified data scientist. She is currently working as a content developer in e-health services. Dr. Yadav has a keen interest in Medical Journalism and is actively involved in Medical Research writing.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751